Work

2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Preface to the Series

Year: 2015

Type: article

Abstract: The majority of us entered the field of allogeneic hematopoietic cell transplantation (HCT) to cure hematologic cancers—by means of immunotherapy. Although this goal has come closer and, with the expansion of transplantation to more high-risk patients, it often seems a miraculous success, chronic graft-versus-host disease (GVHD) has increasingly become the major barrier preventing patients from resuming their normal lives. Unfavorable trends in incidence and severity of chronic GVHD have been observed overall, despite better supportive care and advances in transplantation practice [1].

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2014.12.035

Authors: Steven Z. Pavletic, Georgia B. Vogelsang, Stephanie J. Lee

Institutions: National Institutes of Health, National Cancer Institute, Johns Hopkins University, Fred Hutch Cancer Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650